RecruitingPhase 4NCT05206500

NextGen - Clinical Implication of Next Generation Sequencing

Clinical Implication of Next Generation Sequencing of Urinary Bacteria in Patients With Low Colony Forming Units of Bacteria in Traditional Urine Culture


Sponsor

Wake Forest University Health Sciences

Enrollment

100 participants

Start Date

May 17, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Recently more advanced techniques, including Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) are available to detect bacteria in urine based on bacterial genomes. Comparing to traditional culture, these techniques have more sensitivity and could potentially be of a great help in patients with Colony Count of less than 10,000 and more than zero.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Antibiotic and a medical device called Next Gen for people with urinary tract infections. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAntibiotic

FDA approved and marketed antibiotic treatment for the patients with UTI symptoms and CC \>0 and \<10,000

DEVICENext Gen

Next Generation Sequencing (NGS) is available to detect bacteria in urine based on bacterial genomes.


Locations(1)

Wake Forest Health Sciences

Winston-Salem, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05206500


Related Trials